Abstracts tagged "glucocorticoids"

Abstract Number: 0494 • ACR Convergence 2025
LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates
Matt McClure¹, Catherine Carriere¹, Kierstin Bell¹, Rex Williams², Geoff Kuesters², Emily Sansevere², Dave Nichols², Arthur Tzianabos² and Jay Rothstein¹, ¹Lifordi Immunotherapeutics, Lebanon, NH, ²Lifordi Immunotherapeutics, Burlington, MA
Background/Purpose: Glucocorticoids (GCs) are the most versatile and efficacious anti-inflammatory drugs rheumatologists have available for patients. Unfortunately, prolonged systemic GC exposure leads to unacceptable toxicities,…
Abstract Number: 1038 • ACR Convergence 2025
Real-World Immunosuppressant Treatment Patterns in Lupus Nephritis: A Retrospective Claims Database Analysis in the United States
Anisha Patel¹, Alexandra Miller¹, Lisa Lindsay¹, Danny Sheinson¹, Zhiyu Xia¹, William Pendergraft¹ and Maria Dall'Era², ¹Genentech, Inc., South San Francisco, CA, ²Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: LN is a severe manifestation of SLE requiring intensive management. We aimed to characterize real-world treatment patterns in newly diagnosed patients with LN within…
Abstract Number: 1765 • ACR Convergence 2025
Maintenance of remission with rituximab versus azathioprine in newly diagnosed or relapsing eosinophilic granulomatosis with polyangiitis. A prospective, randomized, controlled, double-blind trial
Xavier Puéchal¹, Grégory Pugnet², Elisabeth Diot³, Claire de Moreuil⁴, Stéphane Jouneau⁵, Thomas Quemeneur⁶, Gabriel Baron⁷, Perrine Smets⁸, Antoine Néel⁹, Thomas Le Gallou¹⁰, Nicolas Noël¹¹, Yurdagül Uzunhan¹², Cloé Comarmond¹³, Geoffrey Urbanski¹⁴, Ygal Benhamou¹⁵, Alice Bérezné¹⁶, Arsène Mekinian¹⁷, Mohamed Hamidou⁹, Julien Campagne¹⁸, Noemie Abisror¹⁹, Benjamin Torreau³, Pascal Cohen²⁰, Loic Guillevin²⁰, Philippe Ravaud⁷ and Benjamin Terrier²¹, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ²CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ³Internal Medicine and Immunology, CHU Tours, Tours, France, ⁴CHU DE BREST, BREST, France, ⁵Respiratory Medicine, Université de Rennes ¹, CHU Pontchaillou, Rennes, France, ⁶Nephrology and Internal Medicine, CH Valenciennes, Valenciennes, France, ⁷Hôtel-Dieu, Université Paris Cité,, Paris, France, ⁸Internal Medicine, CHU Gabriel-Montpied, Clermont-Ferrand, France, ⁹Internal Medicine, CHU Hôtel-Dieu, Nantes, France, ¹⁰Internal Medicine and Clinical Immunology, CHU Rennes Sud, Rennes, ¹¹Internal Medicine and Clinical Immunology, CHU Bicêtre, Bicêtre, ¹²Respiratory Medicine, Hôpital Avicenne, Bobigny, France, ¹³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ¹⁴Internal Medicine and Clinical Immunology, CHU Angers, Angers, France, ¹⁵Internal Medicine, CHU Rouen, Rouen, France, ¹⁶Internal Medicine, CH, Annecy, Annecy, France, ¹⁷Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ¹⁸Internal Medicine, CH Robert Schuman, Metz, France, ¹⁹Internal Medicine, CHU Saint-Antoine,, Paris, France, ²⁰Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ²¹Cochin Hospital, Paris, France
Background/Purpose: The eosinophilic granulomatosis with polyangiitis (EGPA) guidelines recommend considering maintenance therapy after remission to reduce the risk of relapse and toxicity, but data on…
Abstract Number: 0505 • ACR Convergence 2025
Use of Upadacitinib in Real-World Clinical Practice: Patient Characteristics and Glucocorticoid-Sparing Effect
Virginia Ruiz-Esquide¹, Lourdes Mateo², Carolina Pérez García³, Hye Sang-Park⁴, Susana Holgado⁵, María Aparicio⁶, Beatriz Frade⁷, Juan Camilo Sarmiento-Monroy⁸, Annika Nack⁹, Felipe Julio Ramirez Garcia¹⁰, José Gomez-Puerta¹¹ and Raimon Sanmartí¹, ¹Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ²Hospital Trías i Pujol, Barcelona, Catalonia, Spain, ³Hospital del Mar, Barcelona, Spain, ⁴Hospital Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ⁵Hospital Germans Trias i Pujol, Barcelona, Catalonia, Spain, ⁶Hospital Germans Trías i Pujol, Badalona, Catalonia, Spain, ⁷Hospotal Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁸Hospital Clínic Barcelona, Barcelona, Spain, ⁹Hospital Germans Trias i Pujol, Barcelona, Spain, ¹⁰Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, Barcelona, Spain, ¹¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: While clinical trials have demonstrated the efficacy of upadacitinib (UPA), real-world data are essential to understand patient characteristics and assess its effectiveness in routine…
Abstract Number: 1049 • ACR Convergence 2025
Provider Characteristics and Beliefs and Patient Factors Associated with Long-term Glucocorticoid Use in Patients with Rheumatoid Arthritis
Michael George¹, George Reed², Kevin Kane³, Dimitrios Pappas⁴ and Joel Kremer⁵, ¹University of Pennsylvania, Philadelphia, PA, ²University of Massachusetts Chan Medical School, Worcester, MA, ³University of Massachusetts Lowell, Lowell, MA, ⁴CorEvitas, New York, NY, ⁵The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: Guidelines recommend limiting glucocorticoid (GC) use in RA, but 30% of patients continue long-term GCs. Little is known about the influence of provider attitudes…
Abstract Number: 1878 • ACR Convergence 2025
Customized Therapy for SLE: How Disease Severity Influences the Use of Corticosteroids and Biologics in Patients with SLE in the Lupus Federated Data Network (LupusNet) and a US Claims Database
Ashley Orillion¹, Federico Zazzetti², Anna Sheahan³, Clair Blacketer¹, Michel van Speybroeck⁴, Sarah Gasman¹, Reyhan Sonmez⁵, Erika Noss¹, Manuel Ugarte-Gil⁶, Rocío Gamboa-Cárdenas⁷, Víctor Pimentel-Quiroz⁸, Kaleb Michaud⁹, Patti Katz¹⁰, Rangi Kandane-Rathnayake¹¹, Eric Morand¹², Worawit Louthrenoo¹³, Alberta Hoi¹⁴, Yi-Hsing Chen¹⁵, Jiacai Cho¹⁶, Laniyati Hamijoyo¹⁷, Shue Fen Luo¹⁸, Sandra Navarra¹⁹, Mandana Nikpour²⁰, José María Pego-Reigosa²¹, Iñigo Rúa-Figueroa²², Zulema Plaza²³, María Galindo-Izquierdo²⁴, Julia Martínez Barrio²⁵, Jaime Calvo²⁶, Antonio Fernández-Nebro²⁷, Raúl Menor Almagro²⁸, EVA GLORIA TOMERO MURIEL²⁹, Javier Narváez³⁰ and Chetan S. Karyekar³¹, ¹Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ²Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ³Johnson & Johnson, Horsham, PA, USA, Horhsam, PA, ⁴Johnson & Johnson, Beerse, Belgium, Beerse, Belgium, ⁵Capgemini Consulting, Zurich, Switzerland, Zurich, Switzerland, ⁶Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁷Universidad Científica del Sur, Lima, Peru, ⁸Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Perú; Rheumatology Department, Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Perú, Lima, Peru, ⁹University of Nebraska Medical Center, Omaha, NE, ¹⁰UCSF, San Rafael, CA, ¹¹Center for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia, ¹²Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ¹³Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, Chiang Mai, Thailand, ¹⁴Centre for Inflammatory Diseases, Monash University and Department of Rheumatology, Monash Health, Clayton, Victoria, Australia, ¹⁵Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Taichung, Taiwan, Taichung, Taiwan (Republic of China), ¹⁶National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, Singapore, Singapore, ¹⁷Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, Badung, Indonesia, ¹⁸Chang Gung Memorial Hospital, Chang Gung University, Department of Rheumatology, Allergy and Immunology, Taipei, Taiwan, Taoyuan, Taiwan (Republic of China), ¹⁹University of Santo Tomas, Manila, Philippines, ²⁰University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia, ²¹Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ²²Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ²³Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, ²⁴Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ²⁵Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ²⁶Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain, ²⁷Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ²⁸Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ²⁹Hospital Universitario de la Princesa, Madrid, Spain, ³⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ³¹Johnson & Johnson, Spring House, PA, USA, Spring House
Background/Purpose: The management of SLE varies worldwide. Current SLE treatment goals focus on preventing flares, controlling disease activity, and preventing organ damage accrual. LupusNet is…
Abstract Number: 0726 • ACR Convergence 2025
Real-World Avacopan Use in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Insights from United States Claims Data on Outcomes and Adherence
Sebastian E Sattui¹, Elizabeth Ibiloye², Niranjan Kathe³, Sam Oh⁴, Virginia Noxon-Wood⁵, Iman Mohammadi⁵, Laura Moore-Schiltz⁵ and Tingting Li⁶, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Amgen Inc, Thousand Oaks, CA, ³Amgen Inc, San Diego, CA, ⁴Amgen Inc, South San Francisco, CA, ⁵Inovalon, Bowie, MD, ⁶Washington University School of Medicine, St. Louis
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are the most common types of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Treatment-related toxicities, particularly from glucocorticoid…
Abstract Number: 1052 • ACR Convergence 2025
“Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic Prednisone Use
Isabella Hartel¹, Jay Patel¹, Justin Levinson¹, Sancia Ferguson², Carmen Campbell¹, Amannda Weber³, Shelby Gomez⁴, David Gazeley⁵, Ali Duarte-Garcia⁶, Jennifer Barton⁷ and Shivani Garg⁸, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, Madison, WI, ³University of Wisconsin (UW), UW Health, Madison, WI, ⁴University of Wisconsin, School of Pharmacy, Madison, WI, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Mayo Clinic, Rochester, MN, ⁷VA Portland Health Care System/OHSU, Portland, OR, ⁸University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Guidelines recommend limiting chronic prednisone use ( >5 mg/d for >3-6 mos.) given higher risks of fractures, infections, and damage. Yet, patients struggle to…
Abstract Number: 1910 • ACR Convergence 2025
Clinical profile and healthcare resource utilization of patients diagnosed with giant cell arteritis or polymyalgia rheumatica in the US: a real-world cohort study using a large database of administrative health claims
Julie Mouchet¹, Tim Nguyen², Valeria Jordan M.³, G S Ramakrishna⁴, Linda Grinnell-Merrick², Andrew Heaney⁵, Anushka Mitra Das⁵, Pooja Shah⁶ and Evi Zhuleku⁷, ¹Novartis Pharma AG, Basel, Switzerland, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, Tenafly, NJ, ⁴Novartis Healthcare Private Limited, Hyderabad, India, ⁵Novartis Ireland Ltd, Dublin, Ireland, ⁶Cytel Inc, Cambridge, ON, Canada, ⁷Cytel Inc, Berlin, Germany
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are systemic inflammatory conditions which predominantly affect individuals over the age of 50 years. The conditions…
Abstract Number: 0738 • ACR Convergence 2025
Real World Steroid Burden, Treatment Patterns, and Rheumatologists’ Perceptions on Advanced Therapy in Giant Cell Arteritis
Anisha Dua¹, Aditi Kadakia², Patrick Zueger³, Simran Marwaha⁴, Nathaniel Zerad³, Arathi Setty³, William Jones⁴ and Valerie Devauchelle⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²AbbVie Inc, Woburn, MA, ³AbbVie Inc, North Chicago, IL, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵UBO, Brest, France
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in patients 50 years and older. Glucocorticoids (GC) are the mainstay of treatment for GCA…
Abstract Number: 1251 • ACR Convergence 2025
Steroids and Me (Sam): engaging and educating steroid-treated patients via patient advocacy partnerships and internet search channels.
Michelle Petri¹, Martha Stone², John Stone³, meredith Marinaro⁴, Matt Wilkinson⁵, Walter Lentfert⁶, Camille Kotton⁷, Jeffrey Gelfand⁸, Jane McDowell⁹ and Tricha Shivas¹⁰, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Steritas, LLC, Concord, MA, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁴Novartis, Hartford, CT, ⁵UpThereEverywhere, London, United Kingdom, ⁶UpThereEverywhere, Charlotte, NC, ⁷Harvard Medical School, Boston, MA, ⁸UCSF Department of Neurology, Mill Valley, CA, ⁹Queens University Belfast, Belfast, United Kingdom, ¹⁰Foundation for Sarcoidosis Research, Chicago, IL
Background/Purpose: We report on two years of engagement with Sam, a patient-facing program to optimize the use of glucocorticoids and discontinue them when possible. We…
Abstract Number: 2117 • ACR Convergence 2025
Denosumab Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis: A Multi-site Randomized Clinical Trial
Giovanni Adami¹, Kenneth Saag², Gary Cutter³, Rahima Begum³, Elizabeth Dye⁴, Phillip Foster⁵, Camilla Benini⁶, Carmela Dartizio⁶, Davide Gatti⁶ and Maria I. ("Maio") Danila⁷, ¹University of Verona, Italy, Verona, Italy, ²The University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, ⁴UAB, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Verona, Verona, Italy, ⁷University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Prompt anti-resorptive treatment with bisphosphonates after denosumab discontinuation is generally recommended. Glucocorticoid users may not require longer term denosumab and are at greater fracture…
Abstract Number: 0739 • ACR Convergence 2025
Tocilizumab in Giant Cell Arteritis with ischemic vs non-ischemic manifestations
Carmen Secada-Gómez¹, Javier Loricera², Clara Moriano³, Santos Castañeda⁴, Javier Narváez⁵, Vicente Aldasoro Cáceres⁶, Olga Maiz⁷, Rafael B. Melero-González⁸, Paloma Vela Casasempere⁹, Susana Romero-Yuste¹⁰, Jose Luis Callejas¹¹, Eugenio de Miguel¹², Eva Galíndez Agirregoikoa¹³, Francisca Sivera¹⁴, Ivan Ferraz Amaro¹⁵, Julio Sánchez Martín¹⁶ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Hospital León, LEON, Castilla y Leon, Spain, ⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷Hospital Universitario de Donosti, Donostia, Spain, ⁸COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁹Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁰University Hospital Complex of Pontevedra, Pontevedra, Spain, ¹¹Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁴Hospital General Universitario Elda, Elda, Spain, ¹⁵Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁶Hospital Universitario ¹² de Octubre, Madrid, Spain
Background/Purpose: Tocilizumab (TCZ) is the only approved biological drug in the treatment of giant cell arteritis (GCA). However, there are no comparative studies on the…
Abstract Number: 1355 • ACR Convergence 2025
Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance ofbeing off steroids and escalation of therapy at 1 year
Andreu Fernandez Codina¹, Marie-France Valois², Susan J. Bartlett³, Mishquatul Wahed⁴, Hugues Allard-Chamard⁵, Louis Bessette⁶, Glen Hazlewood⁷, Carol Hitchon⁸, Bindee Kuriya⁹, Vivian Bykerk¹⁰ and Janet Pope¹¹, ¹Western University, London, ON, Canada, ²McGill University, Pointe-Claire, QC, Canada, ³McGill University, Beaconsfield, QC, Canada, ⁴Western University, Windsor, ON, Canada, ⁵Université de Sherbrooke, Sherbrooke, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Toronto - Toronto, Toronto, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹University of Western Ontario, London, ON, Canada
Background/Purpose: The 2023 EULAR recommendations for the management of Rheumatoid Arthritis (RA) emphasizes theimportance of limiting the dose and duration of glucocorticoids (GC) used in…
Abstract Number: 2273 • ACR Convergence 2025
Impact of Upadacitinib on Glucocorticoid Reduction in Patients with Moderate-to-Severe RA Who Achieved and Maintained Clinical Remission in the 2-Year UPHOLD Study
FRANK BUTTGEREIT¹, Andrew Ostor², Philip Conaghan³, Ana Romero⁴, Ivan Lagunes⁵, Andrew Garrison⁶, Tianming Gao⁷ and Suzan Attar⁸, ¹Charité University Medicine Berlin, Berlin, Berlin, Germany, ²Australian National University, Canberra, Australia, ³University of Leeds, Leeds, United Kingdom, ⁴AbbVie, Barcelona, Spain, ⁵Abbvie Inc, North Chicago, IL, ⁶AbbVie, USA, North Chicago, IL, ⁷AbbVie, North Chicago, IL, ⁸King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia

Background/Purpose: Glucocorticoids (GCs) are fast-acting drugs used to support csDMARD therapy for RA, but should be used sparingly and for short periods.1 Upadacitinib, an oral…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].